A Critical Appraisal and Implications of the New National Institute for Health and Care Excellence Guideline on Dupilumab for Treating Moderate-To-Severe Atopic Eczema

British Journal of Dermatology - United Kingdom
doi 10.1111/bjd.17329
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Dupilumab Versus Cyclosporine for Treatment of Moderate-To-Severe Atopic Dermatitis in Adults: Indirect Comparison Using the Eczema Area and Severity Index

Acta Dermato-Venereologica
DermatologyMedicine
2019English

National Institute for Health and Clinical Excellence

Journal of Neonatal Nursing
PediatricsMidwiferyMaternity
2011English

Efficacy and Safety of Dupilumab for the Treatment of Moderate-To-Severe Atopic Dermatitis in Adults

Oncotarget
Oncology
2017English

Urological Recommendations From the National Institute for Health and Care Excellence (NICE) Guideline, June 2015: Suspected Cancer: Recognition and Referral

BJU International
Urology
2015English

After the Approval of Dupilumab for Moderate-To-Severe Atopic Dermatitis: What Is Next on the Research Agenda?

British Journal of Dermatology
DermatologyMedicine
2018English

Is National Institute of Clinical Excellence (NICE) Guideline a Nice Guideline?

Translational Andrology and Urology
Reproductive MedicineUrology
2017English

The European TREatment of ATopic Eczema Taskforce (TREAT) Survey; Prescribing Practices in Europe for Phototherapy and Systemic Therapy in Moderate-To-Severe Adult Atopic Eczema Patients

British Journal of Dermatology
DermatologyMedicine
2020English

605 Efficacy and Safety of Dupilumab in Adolescent Patients With Moderate-To-Severe Atopic Dermatitis

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2019English

Stable Angina Medical Therapy Management Guidelines: A Critical Review of Guidelines From the European Society of Cardiology and National Institute for Health and Care Excellence

European Cardiology Review
Cardiovascular MedicineCardiology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy